Market Place
Sourcing Support
ImPact Biotech Presents Updated Padeliporfin VTP Data at AUA 2025
28 Apr 2025 //
GLOBENEWSWIRE
ImPact Biotech Presents New Data on Padeliporfin VTP at AUA 2025
11 Apr 2025 //
GLOBENEWSWIRE
ImPact Biotech Presents Updated Ph 3 Data from Study at SUO 2024
04 Dec 2024 //
GLOBENEWSWIRE
ImPact Biotech Presents Phase 3 Data on Padeliporfin VTP for UTUC
07 Nov 2024 //
GLOBENEWSWIRE
ImPact Biotech to Present Phase 3 Data for Padeliporfin VTP
25 Oct 2024 //
GLOBENEWSWIRE
ImPact Biotech Announces 50% Enrollment In Phase 3 Englighted Trial
27 Sep 2024 //
GLOBENEWSWIRE
ImPact Biotech To Present At Oppenheimer Showcase
25 Sep 2024 //
GLOBENEWSWIRE
ImPact Biotech Receives 13.5M From European Innovation Council
24 Jul 2024 //
GLOBENEWSWIRE
ImPact`s Padeliporfin VTP Data In Low Grade Upper Tract Urothelial Cancer
02 Jun 2024 //
GLOBENEWSWIRE
ImPact`s Padeliporfin Shows Positive Phase 3 Bladder Cancer Data
06 May 2024 //
GLOBENEWSWIRE
ImPact Biotech`s Padeliporfin VTP UTUC Data at Conferences
24 Apr 2024 //
GLOBENEWSWIRE
ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin
20 Dec 2023 //
GLOBENEWSWIRE
ImPact Bio Announces Appointment of Eyal Morag, M.D. as Chief Medical Officer
18 Dec 2023 //
GLOBENEWSWIRE
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Program
04 Aug 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.